Dr Jay to Present Groundbreaking RCT Results on AI Mental Health Intervention at CINP-AsCNP 2025

PARIS - April 9, 2025 - PRLog -- Dr Jay, an AI-powered mental health platform, is pleased to announce that new clinical findings from its flagship product, PATH, have been accepted for presentation at the upcoming CINP-AsCNP 2025 Joint Congress, one of the leading international events in neuropsychopharmacology.

The abstract, titled "A Randomised Controlled Trial of an AI-Enabled Mental Health Intervention for Generalized Anxiety Disorder Symptoms", will be presented as a poster on 17 June 2025 from 10:15 to 10:45 in the Poster & Networking Area. The study highlights PATH's significant efficacy in reducing symptoms of generalized anxiety and depression, particularly among continued users, demonstrating both medium to large effect sizes across multiple timepoints.

"Our findings show strong support for scalable, evidence-based digital interventions in mental health," said Anton Vorobev, CEO of Dr Jay. "We believe AI can play a transformative role in making mental health support more accessible, effective, and stigma-free."

The Dr Jay team will be attending the CINP-AsCNP 2025 Congress and looks forward to engaging with researchers, clinicians, and industry stakeholders who share our commitment to innovative, data-driven mental healthcare. If you are attending and would like to connect with the team during the conference, please reach out to jane@drjay.app to schedule a meeting.

About Dr Jay

Dr Jay is an AI healthcare technology company delivering evidence-based digital interventions for mental health. Backed by a team of clinical psychologists, AI experts, and healthcare leaders, Dr Jay aims to make high-quality mental health support accessible, scalable, and stigma-free.

To learn more, visit www.drjay.ai

Cautionary Note

Dr Jay makes no medical, treatment or health benefit claims about its AI-based interventions. While the PATH app is CE-marked as a Class I medical device and has undergone a randomized controlled trial, these do not imply therapeutic endorsement or regulatory approval for diagnosing, treating, curing, or preventing any disease or condition. The outcomes of the clinical trial are preliminary and exploratory in relation to product claims and intended use and have not been reviewed or approved by regulatory bodies such as the MHRA, EMA, or FDA. Further large-scale, regulator-reviewed studies may be required to confirm the safety and efficacy of the intervention. Any references to clinical outcomes, therapeutic potential, or user benefit are not intended to imply regulatory validation or market readiness. Failure to obtain the necessary approvals or complete the clinical development program may materially impact Dr Jay's ability to commercialize its product or expand into regulated healthcare markets.